3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Conditions
Multiple Myeloma
192
Lymphoma
102
Lymphoma, Non-Hodgkin
90
Leukemia, Myeloid, Acute
89
Precursor Cell Lymphoblastic Leukemia-Lymphoma
81
Myelodysplastic Syndromes
81
Hodgkin Disease
67
Leukemia
66
Neoplasms, Plasma Cell
65
Lymphoma, Large B-Cell, Diffuse
59
Leukemia, Lymphocytic, Chronic, B-Cell
58
Lymphoma, Mantle-Cell
52
Lymphoma, Follicular
49
Burkitt Lymphoma
39
Lymphoma, Large-Cell, Immunoblastic
35
Lymphoma, B-Cell, Marginal Zone
34
Myeloproliferative Disorders
30
Recurrence
28
Hematologic Neoplasms
28
Neuroblastoma
25
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
25
Leukemia, Myeloid, Accelerated Phase
24
Graft vs Host Disease
23
Leukemia, Myelomonocytic, Chronic
22
Leukemia, Myeloid, Chronic-Phase
22
Congenital Abnormalities
21
Immunoglobulin Light-chain Amyloidosis
20
Dendritic Cell Sarcoma, Interdigitating
19
Primary Myelofibrosis
18
Waldenstrom Macroglobulinemia
17
Interventions
Etoposide
3
Carboplatin
3
Vincristine
2
Topotecan
1
Platinum Compounds
1
Melphalan
1
Lasers, Semiconductor
1
Lasers
1
Granulocyte Colony-Stimulating Factor
1
Filgrastim
1
Eye Enucleation
1
Drug Therapy
1
Doxorubicin
1
Cyclophosphamide
1
Cryotherapy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Retinal Neoplasms
×
Melphalan
×
Clear all
NCT02866136
2025-11-24
RETINO2011
Institut Curie
Phase 2
Active not recruiting
133 enrolled